# Investigating the VZV-induced epigenetic modifications of vascular adventitial fibroblasts that contribute to persistent inflammation and VZV vasculopathy

> **NIH NIH P01** · UNIVERSITY OF COLORADO DENVER · 2020 · $463,160

## Abstract

Giant cell arteritis (GCA), the most common systemic vasculitis in individuals >50 years of age, presents with
symptoms and signs including unilateral headache, temporal artery (TA) tenderness, polymyalgia rheumatica,
fatigue, weight loss and elevated serum inflammatory markers. Diagnosis is confirmed by TA biopsy showing
transmural inflammation, medial damage and giant and/or epithelioid cells (GCA-positive). Corticosteroid
treatment is often ineffective and patients develop blindness and stroke. By 2050, a predicted 1.82 million
elderly individuals will develop GCA, of which 36,500 will lose vision resulting total projected cost to the USA
health system of $83.8 billion with $6.5 billion for steroid-induced fracture, $1.1 billion for initial inpatient
management of GCA-associated visual impairment and $76.2 million for ongoing support of elderly with visual
impairment. We have shown GCA is a form of varicella zoster virus (VZV) vasculopathy based on: (1) identical
granulomatous inflammation in GCA-positive TAs and cerebral arteries of intracranial VZV vasculopathy, (2)
presence of VZV antigen, DNA and herpesvirus particles in up to 70% GCA-positive TAs and in VZV-infected
cerebral arteries, (3) importance of the outermost arterial layer (adventitia) as the site of initial inflammation
and VZV infection consistent with virus deposition from nerve fibers that terminate in adventitia, (4)
upregulation of similar cytokines (IL-6, IL-8 and VEGF), and (5) improvement of GCA with acyclovir treatment.
However, the critical question remains: how is a chronic proinflammatory environment maintained in the vessel
wall, especially in vascular adventitial fibroblasts, with a small amount of VZV relative to inflammation? Our
preliminary data showing VZV infection induces proinflammatory cytokines in VZV-infected vascular adventitial
fibroblasts and bystander cells in vitro and in vivo, along with the similarities between adventitial fibroblasts in
GCA and pulmonary arterial hypertension forms the basis of our hypothesis that VZV infection of vascular
adventitial fibroblasts contributes to GCA by initiating epigenetic reprogramming resulting in continued
transcription of host genes associated with proinflammatory cytokine production. We will test this hypothesis by
profiling the inflammatory phenotype (Aim 1) and transcriptome (Aim 2) of adventitial fibroblasts from GCA-
positive and control TAs to determine if VZV infection can induce these changes in gene expression (Aims 1
and 2). The epigenetic modification of regulatory histones and inflammatory transcription factors associated
with host genes accounting for the proinflammatory environment will be determined to provide a mechanism for
their chronic activation (Aim 3). Upon successful completion of these aims, our multi-disciplinary team will
present a new concept by applying advanced technology and develop new algorithms to manage large data
sets to show that vascular adventitial fibroblasts can undergo a...

## Key facts

- **NIH application ID:** 9878046
- **Project number:** 5P01AG032958-12
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **Principal Investigator:** RANDALL J. COHRS
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $463,160
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9878046

## Citation

> US National Institutes of Health, RePORTER application 9878046, Investigating the VZV-induced epigenetic modifications of vascular adventitial fibroblasts that contribute to persistent inflammation and VZV vasculopathy (5P01AG032958-12). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9878046. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*